Cargando…
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
BACKGROUND: We analyzed data retrieved through a PubMed search of randomized, placebo-controlled trials of first-generation antipsychotic long-acting injectables (haloperidol decanoate, bromperidol decanoate, and fluphenazine decanoate), and a company database of paliperidone palmitate, to compare t...
Autores principales: | Gopal, Srihari, Berwaerts, Joris, Nuamah, Isaac, Akhras, Kasem, Coppola, Danielle, Daly, Ella, Hough, David, Palumbo, Joseph |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083982/ https://www.ncbi.nlm.nih.gov/pubmed/21552311 http://dx.doi.org/10.2147/NDT.S17177 |
Ejemplares similares
-
FLUPHENAZINE DECANOATE IN CHRONIC SCHIZOPHRENIA
por: Shukla, G. D.
Publicado: (1981) -
Fluphenazine decanoate‐induced bradycardia: A case report
por: Kamali, Mahsa, et al.
Publicado: (2022) -
PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016) -
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
por: Coppola, Danielle, et al.
Publicado: (2012) -
HALOPERIDOL DECANOATE : ROUTE OF ADMINISTRATION
por: Andrade, Chittaranjan
Publicado: (1998)